By Nancy Lapid May 1 (Reuters) - We also report on a new use for artificial intelligence that could help eliminate some ...

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has granted approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult ...

T cells are crucial components of our immune system, serving as critical protectors against infection and disease.

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Please provide your email address to receive an email when new articles are posted on . The FDA statement on CAR T cells validates early research in autoimmune diseases. The statement points the way ...